Newsroom Bayer

March
24,
2023
| 14:59 PM Europe/Amsterdam
Late-stage development programs with significant potential to drive long-term growth / New R&D strategy and operating model sharpening innovation focus and strengthening early development pipeline in oncology, cardiovascular, neurology & rare
March
23,
2023
| 13:59 PM Europe/Amsterdam
Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline / Fifth major
March
21,
2023
| 10:59 AM Europe/Amsterdam
Holistic approach to improve water use and quality across the entire value chain and contribute to an impactful change / Integration of water stewardship in business and investment decisions / Shaping a water-resilient agriculture system with key
March
20,
2023
| 07:59 AM Europe/Amsterdam
Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer / Additional indication based on data from the pivotal Phase III ARASENS trial 
March
14,
2023
| 12:59 PM Europe/Amsterdam
Ready-to-use AgPowered Services from Bayer running on the new Microsoft Azure Data Manager for Agriculture / Readymade capabilities and robust digital infrastructure allow innovators to focus on differentiated value / Companies, farmers and
March
14,
2023
| 12:45 PM Europe/Amsterdam
Rune Labs’ StriveStudy platform and Emerald Innovations’ Emerald wireless monitoring sensor will passively capture data on Parkinson’s disease impact on function of fifty study participants in BlueRock’s global non-interventional clinical study.  /
March
09,
2023
| 16:14 PM Europe/Amsterdam
Research Triangle Park, N.C.– March 9, 2023 – Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today announced that Gustavo Pesquin will become the company’s next Chief Executive Officer
March
07,
2023
| 08:59 AM Europe/Amsterdam
Basel, Switzerland, March 7, 2023 — A first-of-its-kind collaboration in the consumer health industry is developing a platform aimed at reducing or replacing animal testing using “organ-on-chip” (OoC) technology and interactive computational
March
06,
2023
| 09:59 AM Europe/Amsterdam

New real world study data on reduced risk of adverse kidney outcomes for Xarelto™ compared to VKA

Not intended for U.S. and UK Media - Data presented at American College of Cardiology (ACC.23)

In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced
March
01,
2023
| 11:59 AM Europe/Amsterdam
European Commission granted approval of Nubeqa™ (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Approval is based on Phase III ARASENS trial data
March
01,
2023
| 07:59 AM Europe/Amsterdam
Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials,

Sign up for our Newsletter

We will keep you informed about the latest news.